Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemia·2026
Same author

No association of prior administration of selected vaccines with lymphoma prognosis.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026
Same author

GPR15-guided CD8<sup>+</sup> T regulatory cells control intestinal inflammation.

Nature·2026
Same author

Can we target CTCL clonal evolution and improve outcomes?

Blood·2026
Same author

HNRNPU Mutations Redirect Cell Cycle Control to E2F in MYC-Driven Lymphomas.

Blood advances·2026
Same journal

Bridging two worlds: harmonizing pediatric and adult ALL.

Blood advances·2026
Same journal

Reaching consensus in relapsed/refractory ALL in AYAs.

Blood advances·2026
Same journal

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same journal

Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma.

Blood advances·2026
Same journal

Venous Thromboembolism in Women on Estrogen Therapy: Presentation, Management, and Outcomes in the RIETE registry.

Blood advances·2026
Same journal

Diagnosis of NK-Large Granular Lymphocytic Leukemia.

Blood advances·2026
See all related articles

Related Experiment Video

Updated: Sep 15, 2025

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

12.4K

High-grade B-cell lymphoma, not otherwise specified: an LLMPP study.

Brett J Collinge1,2, Laura K Hilton1,3, Jasper Chun Hei Wong1

  • 1Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.

Blood Advances
|July 17, 2025
PubMed
Summary
This summary is machine-generated.

Molecular profiling reveals high-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) is a heterogeneous disease with features of diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). This finding supports HGBCL-NOS inclusion in DLBCL clinical trials.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K

Related Experiment Videos

Last Updated: Sep 15, 2025

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry
07:39

Isolation of CD4+ T-cells and Analysis of Circulating T-follicular Helper cTfh Cell Subsets from Peripheral Blood Using 6-color Flow Cytometry

Published on: January 7, 2019

12.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.2K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • High-grade B-cell lymphoma, not otherwise specified (HGBCL-NOS) is rare, with an evolving definition and diagnostic challenges.
  • Understanding the molecular characteristics of HGBCL-NOS is crucial for accurate diagnosis and treatment.

Purpose of the Study:

  • To molecularly characterize HGBCL-NOS and compare it with diffuse large B-cell lymphoma (DLBCL-NOS) and Burkitt lymphoma (BL).
  • To assess the utility of existing molecular classifiers in HGBCL-NOS.

Main Methods:

  • Analysis of 92 HGBCL-NOS tumors using molecular profiling techniques.
  • Comparison with DLBCL-NOS and BL cohorts.
  • Application of LymphGen classifier and a DLBCL-NOS vs. BL classifier.
  • Centralized pathology review.

Main Results:

  • HGBCL-NOS exhibits a heterogeneous molecular landscape, with features of both DLBCL-NOS and BL, including enrichment of BL-associated genes (MYC-rearrangement, dark zone signature).
  • LymphGen classifier assigned subtypes to 34% of HGBCL-NOS, with 31% of activated B-cell-like (ABC) cases classified as MCD.
  • Pathology review reclassified nearly half of cases as DLBCL-NOS without identifying a more homogenous HGBCL-NOS subgroup.

Conclusions:

  • Molecular testing can assign a subset of HGBCL-NOS to established categories.
  • Due to its rarity and diagnostic complexity, HGBCL-NOS should be considered for inclusion in biomarker-driven DLBCL clinical trials.